RankingsPricing
  1. US-listed companies
  2. Aldeyra Therapeutics, Inc.
  3. Financials
  4. Cash and cash equivalents

Aldeyra Therapeutics, Inc.ALDX

Market cap
$300.08M
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 202455-61.82%
Dec 31, 2023143-1.11%
Dec 31, 2022144-37.15%
Dec 31, 2021230+195.14%
Dec 31, 202078+75.25%
Dec 31, 201944-6.19%
Dec 31, 201847+136.51%
Dec 31, 201720+66.65%
Dec 31, 201612-17.98%
Dec 31, 201515+71.79%
Dec 31, 20149

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)